clinical trial efficacy of autologous cellular micrografts in androgenic alopecia
Authors: Chunmei Wang , Xian Hua , Yang Bin , Alkouz Ziad 
Published: February 2023

Abstract
Purpose: Autologous cellular micrografts (ACM) is a novel treatment method in hair loss and androgenic alopecia. Androgenetic alopecia, androgenic alopecia, pattern hair loss, male pattern baldness, female pattern baldness all of them the same meaning means a decrease in the hair follicle size, which could be related to the loss of hair follicle stem cells or progenitor cell. in this study we worked on a clinical study for a patient who reported with androgenic alopecia and pattern baldness we used a new novel treatment method in hair loss called(ACM); Autologous Micrografting Technology is an innovative, simple and effective regenerative method to obtain Autologous micrografts using Rigenera technology. AMT protocols are based on stimulating self- regeneration by activating native progenitor cells located in the homologous tissues, through a simple process, without risks to the patient and great therapeutic potential. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens which affects up to 20% of males and females. It is characterized by progressive loss of terminal hair of the scalp any time after puberty, in a characteristic distribution in both males and females. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women the frontal hairline is typically spared with diffuse apical hair loss noted as a wider anterior part of the hair. White patients are most affected followed by Asians and African Americans, then Native Americans and Eskimos. The incidence approximates the age in Caucasian males, with 50% affected by 50 years old and up to 80% affected by 70 years old. In females, the disorder is quite common, with an increase in incidence after menopause. AGA is a disorder primarily determined by a genetic predisposition for hair follicles to have an excessive response to androgens.
Aims: The aim is to conduct clinical studies for the treatment of androgenetic alopecia (AGA) from the second stage to the fourth stage of baldness on a group of 25 patients from the age of 23 years to the age of 64 years, males and females who was diagnosed with a AGA and chronic hair loss problems using a Autologous cellular micrografts Technology by the new device called the Regenera active device ,which extracts stem cells , progenitor cells and Growth factors from hair follicles and injects them in balding areas and weak areas, then results appear from one to 4 months and make comparisons before and after treatment.
Methods: A group of patients, numbering 25 patients gender male and female, complained of genetic baldness and pattern hair loss on the crown( vertex) of the scalp and frontal part of the scalp, for a period between one to seven years.The diagnosis was made by dermoscope and by the pathological and historical condition of the patients and by the use of phototricograms and the stages of alopecia was determined by using Norwood scale and Sinclair Scale.We used Autologous Micrografting Technology is an innovative, simple and effective regenerative method to obtain Autologous micrografts using Rigenera technology. AMT protocols are based on stimulating self- regeneration by activating native progenitor cells located in the homologous tissues, through a simple process, without risks to the patient and great therapeutic potential.AMT obtains injectable micrografts composed of cells stem cells and progenitor cells , extracellular matrix, and growth factors derived from the patient's own cells, with no other manipulation than mechanical disaggregation.
Results: Depending on the scalp region, A Paired samples t-test was conducted to determine the effect of the ACM treatment of androgenic alopecia (AGA) on hair. The results indicate that there was significant increase in all hair parameters including hair count (+41.56 hair/cm2), Hair density (+27.09 hair/cm2), Anagen (+5.89%), Telogen (+6.55%), Density vellus hair (5.43 hair/cm2), Density terminal (19.16 hair/cm2), Ratio vellus hair (3.29 %), Ratio terminal hair (4.29 %). A response to treatment was observed in all patients. Moreover, a gender and age -specific effect of treatment was observed.
Conclusion: According to clinical trials conducted on AGA patients and the wonderful results, ACM is a promising, effective, and fast treatment and there are no dangerous side effects for the patient, nearly 90% of patients have impressive results.